# EDGAR Filing Document

**Accession Number:** 0001560293
**File Stem:** 0001213900-26-013278
**Filing Date:** 2026-2
**Character Count:** 9144
**Document Hash:** 36039b06135b2a99b71f7127b3e458bc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-013278.hdr.sgml**: 20260206

**ACCESSION NUMBER**: 0001213900-26-013278

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20260205

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260206

**DATE AS OF CHANGE**: 20260206

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tenon Medical, Inc.
- **CENTRAL INDEX KEY:** 0001560293
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 455574718
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41364
- **FILM NUMBER:** 26607735

**BUSINESS ADDRESS:**
- **STREET 1:** 104 COOPER CT.
- **CITY:** LOS GATOS
- **STATE:** CA
- **ZIP:** 95032
- **BUSINESS PHONE:** (408) 649-5760

**MAIL ADDRESS:**
- **STREET 1:** 104 COOPER CT.
- **CITY:** LOS GATOS
- **STATE:** CA
- **ZIP:** 95032

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported):

**<u>February 5, 2026</u>**

**<u>TENON MEDICAL, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41364** | **45-5574718** |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer |
| of incorporation) |  | Identification No.) |

---

---

| | |
|:---|:---|
| **104 Cooper Court**<br>**Los Gatos, CA** | **95032** |
| (Address of principal executive offices) | (Zip Code) |

---

**<u>(408) 649-5760</u>**

(Registrant's telephone number, including area code)

**<u>N/A</u>**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | TNON | The Nasdaq Stock Market LLC |
| Warrants | TNONW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02 Results of Operations and Financial Condition.**

On February 5, 2026, Tenon Medical, Inc., a Delaware corporation (the "Company"), issued a press release announcing unaudited revenue for the fourth quarter of 2025 totaling $1.45 to $1.48 million, which represents an approximately 90% increase in revenue year-over-year, as compared to the fourth quarter of 2024 fiscal year, as well as unaudited revenue for the 2025 fiscal year totaling $3.91 to $3.94 million, which represents an approximately 20% increase in revenue year-over-year, as compared to 2024 fiscal year.

The Company also stated in the press release that it plans to release financial results for the fourth quarter and full year 2025 ended December 31, 2025 after market close on Thursday, March 19, 2026, and hold a conference call on the same day at 4:30 p.m. (Eastern Time) to discuss its financial results in further details.

**Item 8.01 Other Events.**

A copy of the press release referenced in Item 2.02 of this Current Report on Form 8-K is as Exhibit 99.1 to this Current Report on Form 8-K.

The disclosure under Item 8.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information provided herein shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibits are being filed herewith:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release of Tenon Medical, Inc., dated February 5, 2026.](ea027592001ex99-1_tenon.htm) |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: February 6, 2026 | **TENON MEDICAL, INC.** | **TENON MEDICAL, INC.** |
|  | (Registrant) | (Registrant) |
|  | By: | */s/ Steven M. Foster* |
|  | Name: | Steven M. Foster |
|  | Title: | Chief Executive Officer and President |

---

## Exhibit 99.1

**Exhibit 99.1** 

**Tenon Medical, Inc. Sets Date for Fourth Quarter and Full Year 2025 Earnings, Reaffirms <br> Expected Revenues** 

 

*Fourth Quarter 2025 Revenue of $1.45 to $1.48 Million, representing growth of ~90% year over <br> year*

 

*Full Year 2025 Revenue of $3.91 to $3.94 Million, representing growth of ~20% year over year*

**Los Gatos, CA, February 5, 2026 -** Tenon Medical, Inc. (NASDAQ: TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced plans to release financial results for the fourth quarter and full year 2025 ended December 31, 2025 after market close on Thursday, March 19, 2026. The Company will also hold a conference call on the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.

---

| | |
|:---|:---|
| &nbsp;&nbsp; **Date:** | &nbsp;&nbsp;Thursday, March 19, 2026 |
| &nbsp;&nbsp;**Time:** | &nbsp;&nbsp;4:30 p.m. Eastern time |
| &nbsp;&nbsp;**Dial-in:** | &nbsp;&nbsp;1-877-407-0792 |
| &nbsp;&nbsp;**International Dial-in:** | &nbsp;&nbsp;1-201-689-8263 |
| &nbsp;&nbsp;**Webcast:** | &nbsp;&nbsp;TNON Conference Call |

---

Please dial in at least 10 minutes before the start of the call to ensure timely participation.

An audio playback of the call will be available through April 2, 2026, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13758268.

**About Tenon Medical, Inc.**

Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022, Tenon is focused on three commercial opportunities with its System in the SI Joint market which include: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) Augmenting spinal fusion. For more information, please visit www.tenonmed.com.

*The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAIL<sup>TM</sup>, and SImmetry+ are also trademarks of Tenon Medical, Inc.*

**Investor Contact** 

Shannon Devine

MZ North America

203-741-8811

tenon@mzgroup.us